Real-World study tracks Selumetinib's impact on NF1 tumors in children

NCT ID NCT05891847

Terminated Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study observes children aged 3 to 18 with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas and are starting treatment with selumetinib. Researchers will track how well the drug shrinks or stabilizes tumors, how long patients stay on treatment, and any side effects. The goal is to see how selumetinib works in everyday medical practice in Russia.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: selumetinib
What this could lead to: If successful, this study could confirm that selumetinib effectively shrinks or stabilizes these tumors in children with NF1 outside of controlled trials.
What could go wrong: This is an observational study, not a controlled experiment, so results may be less reliable. Selumetinib can cause side effects like nausea, diarrhea, and skin issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROFIBROMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neurofibroma neurofibromatosis type 1 plexiform neurofibroma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROFIBROMA

Contacts and locations

Show contact details

Locations

Research Site

Moscow, Moscow, 123112, Russia
Research Site

Moscow, Russia
Research Site

Novosibirsk, Russia
Research Site

Saint Petersburg, Russia
Research Site

Yekaterinburg, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.